A novel animal model for hemangiomas: Inhibition of hemangioma development by the angiogenesis inhibitor TNP-470

Cancer Research

Volumn 59, Issue 10, 1999, Pages 2376-2383

  Liekens, Sandra ^a,b   Verbeken, Erik ^a   Vandeputte, Michel ^a   De Clercq, Erik ^a   Neyts, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INCIDENCE; CANCER MODEL; CANCER MORTALITY; CELL GROWTH; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEMANGIOMA; IMMUNOHISTOCHEMISTRY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME;

ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; BRAIN NEOPLASMS; CELL TRANSFORMATION, VIRAL; CYCLOHEXANES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HEMANGIOMA; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; INTERFERON INDUCERS; MALE; NEOVASCULARIZATION, PATHOLOGIC; POLY I-C; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; RATS; SESQUITERPENES; SEX FACTORS; TUMOR VIRUS INFECTIONS; VIRAL LOAD;

EID: 0033563118     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Requena, L., and Sangueza, O. P. Cutaneous vascular proliferation. Part II. Hyperplasias and benign neoplasms. J. Am. Acad. Dermatol., 37: 887-919, 1997.
2. Fishman, S. J., and Mulliken, J. B. Hemangiomas and vascular malformations of infancy and childhood. Pediatr. Clin. North Am., 40: 1177-1200, 1993.
3. Achauer, B. M., Chang, C. J., and Vander Kam, V. M. Management of hemangioma of infancy: review of 245 patients. Plast. Reconstr. Surg., 99: 1301-1308, 1997.
4. Sadan, N., and Wolach, B. Treatment of hemangiomas of infants with high doses of prednisone. J. Pediatr., 128: 141-146, 1996.
5. Landthaler, M., Hohenleutner, U., and el Raheem, T. A. Laser therapy of childhood haemangiomas. Br. J. Dermatol., 133: 275-81, 1995.
6. Bauman, N. M., Burke, D. K., and Smith, R. J. Treatment of massive or life-threatening hemangiomas with recombinant α(2a)-interferon. Otolaryngol. Head Neck Surg., 117: 99-110, 1997.
7. Castello, M. A., Ragni, G., Antimi, A., Todini, A., Patti, G., Lubrano, R., Clerico, A., and Calisti, A. Successful management with Interferon α-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma. Med. Pediatr. Oncol. 28: 213-215, 1997.
8. Pepper, M. S. Manipulating angiogenesis: from basic science to the bedside. Arterioscler. Thromb. Vasc. Biol., 17: 605-619, 1997.
9. Ricketts, R. R., Hatley, R. M., Corden, B. J., Sabio, H., and Howell, C. G. Interferon α-2a for the treatment of complex hemangiomas of infancy and childhood. Ann. Surg., 219: 605-614, 1994.
10. Takahashi, K., Mulliken, J. B., Kozakewich, H. P. W., Rogers, R. A., Folkman, J., and Ezekowitz, R. A. B. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest., 93: 2357-2364, 1994.
11. Martin-Padura, I., De Castellarnau, C., Uccini, S., Pilozzi, E., Natali, P. G., Nicotra, M. R., Ughi, F., Azzolini, C., Dejana, E., and Ruco, L. Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. J. Pathol., 175: 51-57, 1995.
12. Folkman, J., and Klagsbrun, M. Angiogenic factors. Science (Washington DC), 235: 442-447, 1987.
13. O'Reilly, M. S., Brem, H., and Folkman, J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J. Pediatr. Surg., 30: 325-330, 1995.
14. Garlanda, C., Parravicini, C., Sironi, M., De Rossi, M., Wainstock de Calmanovici, R., Carozzi, F., Bussolino, F., Colotta, F., Mantovani, A., and Vecchi, A. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc. Natl. Acad. Sci. USA, 91: 7291-7295, 1994.
15. Williams, R. L., Risau, W., Zerwes, H-G., Drexler, H., Aguzzi, A., and Wagner, E. F. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell, 57: 1053-1063, 1989.
16. Gualandris, A., Rusnati, M., Belleri, M., Nelli, E. E., Bastaki, M., Molinari-Tosatti, M. P., Bonardi, F., Parolini, S., Albini, A., Morbidelli, L., Ziehe, M., Corallini, A., Possati, L., Vacca, A., Ribatti, D., and Presta, M. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ., 7: 147-160, 1996.
17. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond.). 348: 555-557, 1990.
18. Sasaki, A., Alcalde, R. E., Nishiyama, A., Lim, D. D., Mese, H., Akedo, H., and Matsumura, T. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res., 58: 462-467, 1998.
19. Wassberg, E., and Christofferson, R. Angiostatic treatment of neuroblastoma. Eur. J. Cancer. 33: 2020-2023, 1997.
20. Tanaka, T., Konno, H., Matsuda, I., Nakamura, S., and Baba, S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res., 55: 836-839, 1995.
21. Yamaoka, M., Yamamato, T., Ikeyama, S., Sudo, K., and Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res., 53: 233-236, 1993.
22. Dezube, B. J., Von Roenn, J. H., Holden Wiltse, J., Cheung, T. W., Remick, S. C., Cooley, T. P., Moore, J., Sommadossi, J. P., Shriver, S. L., Suckow, C. W., and Gill, P. S. Fumagillin analog in the treatment of Kaposi's sarcoma: a Phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J. Clin. Oncol., 16: 1444-1449, 1998.
23. Barinaga, M. Designing therapies that target tumor blood vessels. Science (Washington DC), 275: 482-484, 1997.
24. Liekens, S., Andrei, G., Vandeputte, M., De Clercq, E., and Neyts, J. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res., 58: 2562-2567, 1998.
25. Kiefer, F., Courtneidge, S., and Wagner, E. F. Oncogenic properties of the middle T antigens of polyomaviruses. Adv. Cancer Res., 64: 125-156, 1994.
26. Bautch, V. L., Toda, S., Hassell, J. A., and Hanahan, D. Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene. Cell, 51: 529-538, 1987.
27. Courtneidge, S. A., and Smith, A. E. Polyoma virus transforming protein associates with the product of the c-src cellular gene. Nature (Lond.), 303: 435-439, 1983.
28. Horak, I. D., Kawakami, T., Gregory, F., Robbins, K. C., and Bolen, J. B. Association of p60fyn with middle tumor antigen in murine polyomavirus-transformed rat cells. J. Virol., 63: 2343-2347, 1989.
29. Kornbluth, S., Sudol, M., and Hanafusa, H. Association of the polyomavirus middle-T antigen with c-yes protein. Nature (Lond.), 315: 171-173, 1987.
30. Dilworth, S. M., Brewster, C. E., Jones, M. D., Lanfrancone, L., Pelicci, G., and Pelicci, P. G. Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature (Lond.), 367: 87-90, 1994.
31. Courtneidge, S. A., and Heber, A. An 81 kd protein complexed with middle T antigen and pp60c-src: a possible phosphatidylinositol kinase. Cell, 50: 1031-1037, 1987.
32. Toda, K., Tsujioka, K., Maruguchi, Y., Ishii, K., Miyachi, Y., Kuribayashi, K., and Imamura, S. Establishment and characterization of a tumorigenic vascular endothelial cell line (F-2). Cancer Res., 50: 5526-5530, 1990.
33. Sato, N., Sato, T., Takahashi, S., and Kikuchi, K. Establishment of murine endothelial cell lines that develop angiosarcomas in vivo: brief demonstration of a proposed animal model for Kaposi's sarcoma. Cancer Res., 46: 362-366, 1986.